Equine Collagen Injectables: What Practitioners Should Know

Collagen production declines steadily from around the mid-twenties, and by the fourth decade most patients have lost a meaningful proportion of what they started with — a gradual process that underlies much of what patients describe as fine lines, reduced firmness and a duller complexion. Alongside hyaluronic acid-based approaches, equine-derived collagen injectables represent a distinct category worth understanding on their own terms.

What Equine Collagen Injectables Are

Products in this category are derived from Type I collagen sourced from horse tendon — the fibrous connective tissue linking bone to muscle — processed into a lyophilised (freeze-dried) powder for reconstitution and injection. LinErase is the best-known example, developed by an Italian biomedical laboratory and carrying CE marking as a Class III medical device. It is distinct in mechanism from hyaluronic acid skinboosters: rather than primarily attracting and holding water in the skin, it is intended to stimulate the skin's own fibroblast activity, supporting native Type III collagen production as part of the tissue's response.

How It Is Positioned in a Treatment Plan

Equine collagen is generally discussed for concerns including fine lines, deeper wrinkles and folds, and more advanced photo-ageing, positioning it closer to a biostimulatory skin-quality treatment than to a purely hydrating one. As with other biostimulatory approaches, results tend to build across a course of sessions rather than appearing after a single treatment, which is worth setting clearly in patient expectations at consultation. Type I collagen has a long history of use in wound and scar management, which is part of the rationale for its more recent application in skin rejuvenation.

Regulatory and Safety Considerations

Because the material is animal-derived, hypoallergenicity claims and processing standards are a relevant part of due diligence for any practice considering this category, alongside the CE certification and Class III medical device status that governs its use in the UK and other European markets. As with any injectable, a full patient history — including any known animal-protein sensitivities — is part of standard assessment before treatment.

Complementary Skincare

Equine-derived formulations extend beyond the injectable itself. Topical products based on equine placenta extract, such as horse placenta serum, and supporting products including barrier-focused UV protection like LNC UV Protector, are sometimes recommended alongside the injectable course to support skin condition between sessions and protect the investment made in a collagen-stimulating treatment.

How It Compares With HA-Based Options

The practical distinction from HA skinboosters and biorevitalisation is composition and mechanism rather than the broad category of concern addressed — both aim to improve skin quality rather than add structural volume. Equine collagen leans on a biostimulatory, protein-based mechanism with a longer track record in wound healing; HA-based skinboosters lean on a substance naturally abundant in skin itself, with a well-established safety and reversibility profile. Neither is universally superior; the choice depends on patient history, the specific concern being addressed, and practitioner familiarity with each product category.

The Takeaway

Equine-derived collagen injectables are a distinct, established category within skin-quality treatment, mechanistically different from HA skinboosters and worth understanding as a separate tool rather than a variation on the same theme. As with any biostimulatory treatment, results build over a course of sessions and are best set against realistic patient expectations from the outset.

To review skin-quality injectables and complementary options, browse the skinboosters range.